Apr. 23 at 4:35 PM
$ALZN They have until May 4th to come up with a solution to keep from getting delisted. Harvard is starting a clinical trial for ALZ and lithium orotate, as well as John Hopkins. Orotate is a organic lithium that doesn't bind to amyloid plague, but it's over the counter and doesn't have patent. Question is will a bigger biotech risk and partner with Alzn now that these two major hospital are moving forward with lithium orotate, since AL001 is also an organic lithium that doesn't bind and it has a patent. https://news.harvard.edu/gazette/story/2026/01/an-alzheimers-breakthrough-10-years-in-the-making/
